Indantadol

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Indantadol
(IUPAC) ime
N-(2,3-dihidro-1H-inden-2-il)glicinamid
Klinički podaci
Identifikatori
CAS broj 202844-10-8
ATC kod nije dodeljen
ChemSpider[1] 16017060
UNII Z3867B9SQP YesY
Hemijski podaci
Formula C11H14N2O 
Mol. masa 190,24 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status Nije kontrolisana supstanca
Način primene Oralno

Indantadol (CHF-3381, V-3381) je lek koje je izučavan za moguću primenu kao antikonvulsant i neuroprotectiv, i koji se razvija kao potencijalni tretman neuropatičkog bola i hroničnog kašlja u Evropi.[2][3][4][5][6][7][8][9] On takođe deluje kao kompetitivni, reverzibilni, i neselektivni inhibitor monoaminske oksidaze,[6][7][10] i kao nekompetitivni antagonist NMDA receptora niskog afiniteta.[2][3][11]

Reference[uredi - уреди | uredi kôd]

  1. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.  edit
  2. 2,0 2,1 Villetti G, Bregola G, Bassani F, et al. (June 2001). „Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology 40 (7): 866–78. DOI:10.1016/S0028-3908(01)00026-0. PMID 11378157. http://linkinghub.elsevier.com/retrieve/pii/S0028390801000260. 
  3. 3,0 3,1 Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). „Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior 70 (1): 157–66. DOI:10.1016/S0091-3057(01)00591-3. PMID 11566153. http://linkinghub.elsevier.com/retrieve/pii/S0091-3057(01)00591-3. 
  4. Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). „Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport 13 (16): 2071–4. DOI:10.1097/00001756-200211150-00016. PMID 12438928. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0959-4965&volume=13&issue=16&spage=2071. 
  5. Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). „Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804–14. DOI:10.1124/jpet.103.050039. PMID 12750440. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=12750440. 
  6. 6,0 6,1 „CHF 3381”. Drugs in R&D 5 (1): 28–30. 2004. PMID 14725488. 
  7. 7,0 7,1 Mattia C, Coluzzi F (September 2007). „Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain”. IDrugs : the Investigational Drugs Journal 10 (9): 636–44. PMID 17786847. 
  8. „IN-STEP Phase IIb study results”. http://www.vernalis.com/media-centre/latest-releases/567-in-step-phase-iib-study-results-. 
  9. „Vernalis initiates Pilot Study of V3381 in patients with chronic cough”. http://www.vernalis.com/media-centre/latest-releases/2009-releases/389. 
  10. Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). „CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain 7 (8): 565–74. DOI:10.1016/j.jpain.2006.02.004. PMID 16885013. http://linkinghub.elsevier.com/retrieve/pii/S1526-5900(06)00544-X. 
  11. Barbieri M, Bregola G, Buzzi A, et al. (August 2003). „Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology 139 (7): 1333–41. DOI:10.1038/sj.bjp.0705381. PMC 1573965. PMID 12890713. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1573965/. 

Vidi još[uredi - уреди | uredi kôd]

Spoljašnje veze[uredi - уреди | uredi kôd]